Henrique Lima de Oliveira

Ms. Henrique Lima de Oliveira

Universidade Federal de Goiás, Goiânia, Goiás, Brazil
orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
Antonio da Silva Menezes JuniorAntonio da Silva Menezes Junior
Antonio da Silva Menezes Junior
Ana Luísa Guedes de França e SilvaAna Luísa Guedes de França e Silva
Ana Luísa Guedes de França e Silva
Henrique Lima de OliveiraHenrique Lima de Oliveira
Henrique Lima de Oliveira
KLKhissya Beatryz Alves de Lima
Khissya Beatryz Alves de Lima
IPIane de Oliveira Pires Porto
Iane de Oliveira Pires Porto
AJAguinaldo F. Freitas Jr
Aguinaldo F. Freitas Jr
Hypertrophic cardiomyopathy (HCM) is a heart condition characterized by cellular and metabolic dysfunction, with mitochondrial dysfunction playing a crucial role. Although the direct relationship between genetic mutations and mitochondrial dysfunction remains unclear, targeting mitochondrial dysfunction presents promising opportunities for treatment, as there are currently no effective treatments available for HCM. This review adhered to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis Extension for Scoping Reviews guidelines. Searches were conducted in databases such as PubMed, Embase, and Scopus up to September 2023 using “MESH terms”. Bibliographic references from pertinent articles were also included. Hypertrophic cardiomyopathy (HCM) is influenced by ionic homeostasis, cardiac tissue remodeling, metabolic balance, genetic mutations, reactive oxygen species regulation, and mitochondrial dysfunction. The latter is a common factor regardless of the cause and is linked to intracellular calcium handling, energetic and oxidative stress, and HCM-induced hypertrophy. Hypertrophic cardiomyopathy treatments focus on symptom management and complication prevention. Targeted therapeutic approaches, such as improving mitochondrial bioenergetics, are being explored. This includes coenzyme Q and elamipretide therapies and metabolic strategies like therapeutic ketosis. Understanding the biomolecular, genetic, and mitochondrial mechanisms underlying HCM is crucial for developing new therapeutic modalities.

29 December 2025 in Cells
Verified
Journal Article
Open access
PDF file
Antonio da Silva Menezes JuniorAntonio da Silva Menezes Junior
Antonio da Silva Menezes Junior
Henrique Lima de OliveiraHenrique Lima de Oliveira
Henrique Lima de Oliveira
KLKhissya Beatryz Alves de Lima
Khissya Beatryz Alves de Lima
SBSilvia Marçal Botelho
Silvia Marçal Botelho
MAMelissa Avelino
Melissa Avelino
Background: Hypertrophic cardiomyopathy (HCM) is increasingly recognized as a disorder shaped not only by sarcomeric mutations but also by complex immunogenetic and metabolic interactions. Emerging transcriptomic and single-cell analyses implicate immune dysregulation, RNA methylation, and necroptosis as critical modulators of myocardial remodeling. Objectives: This scoping review synthesizes bioinformatic, transcriptomic, and experimental data to delineate the immunogenetic architecture of HCM and identify candidate molecular targets for immune–metabolic modulation. Methods: Following Joanna Briggs Institute and PRISMA-ScR guidelines, we systematically searched PubMed, Embase, Web of Science, and GEO through September 2025 for studies evaluating immune infiltration, RNA regulation, and necroptosis in human HCM. Data were narratively synthesized across histologic, clinical, and multi-omics domains. Results: Among 8191 screened records, 25 studies met the inclusion criteria. Key immune–epigenetic regulators included the lncRNA–mRNA pair MIR210HG–BPIFC, m6A readers IGFBP3 and YTHDC1, and necroptosis gene JAK2. The HCM myocardium exhibited the depletion of reparative M2 macrophages and Tregs; enrichment of cytotoxic CD8+ T cells; and activation of the TNFα–NFκB, IL-6–JAK–STAT3, and PI3K–Akt pathways. Machine learning biomarkers (RASD1, FCN3, and PIK3R1) exhibited diagnostic accuracy (AUC > 0.85). Drug target predictions identified ruxolitinib and celecoxib as potential immunometabolic modulators (agents predicted to modulate both immune and metabolic pathways based on gene expression signatures). Conclusions: These findings support a hypothesis that HCM may involve immunogenetic mechanisms, rather than being exclusively sarcomeric in nature, although this remains to be validated. The integration of molecular and imaging biomarkers may enable precision immunotherapy, redefining HCM from a structural cardiomyopathy to a biologically stratified condition.

Verified
Journal Article
Open access
PDF file
Antonio da Silva Menezes JuniorAntonio da Silva Menezes Junior
Antonio da Silva Menezes Junior
ASAna Lívia Félix e Silva
Ana Lívia Félix e Silva
LSLouisiany Raíssa Félix e Silva
Louisiany Raíssa Félix e Silva
KLKhissya Beatryz Alves de Lima
Khissya Beatryz Alves de Lima
Henrique Lima de OliveiraHenrique Lima de Oliveira
Henrique Lima de Oliveira
Background/Objective: Atrial fibrillation [AF] is the most common arrhythmia encountered in clinical practice and significantly increases the risk of stroke, peripheral embolism, and mortality. With the rapid advancement in artificial intelligence [AI] technologies, there is growing potential to enhance the tools used in AF detection and diagnosis. This scoping review aimed to synthesize the current knowledge on the application of AI, particularly machine learning [ML], in identifying and diagnosing AF in clinical settings. Methods: Following the PRISMA ScR guidelines, a comprehensive search was conducted using the MEDLINE, PubMed, SCOPUS, and EMBASE databases, targeting studies involving AI, cardiology, and diagnostic tools. Precisely 2635 articles were initially identified. After duplicate removal and detailed evaluation of titles, abstracts, and full texts, 30 studies were selected for review. Additional relevant studies were included to enrich the analysis. Results: AI models, especially ML-based models, are increasingly used to optimize AF diagnosis. Deep learning, a subset of ML, has demonstrated superior performance by automatically extracting features from large datasets without manual intervention. Self-learning algorithms have been trained using diverse data, such as signals from 12-lead and single-lead electrocardiograms, and photoplethysmography, providing accurate AF detection across various modalities. Conclusions: AI-based models, particularly those utilizing deep learning, offer faster and more accurate diagnostic capabilities than traditional methods with equal or superior reliability. Ongoing research is further enhancing these algorithms using larger datasets to improve AF detection and management in clinical practice. These advancements hold promise for significantly improving the early diagnosis and treatment of AF.

16 October 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
Antonio da Silva Menezes JuniorAntonio da Silva Menezes Junior
Antonio da Silva Menezes Junior
MAMelissa Avelino
Melissa Avelino
Henrique Lima de OliveiraHenrique Lima de Oliveira
Henrique Lima de Oliveira
KLKhissya Beatriz Alves de Lima
Khissya Beatriz Alves de Lima
SBSilvia Marçal Botelho
Silvia Marçal Botelho
Background: Immune dysregulation has emerged as a central mechanism in atrial fibrillation (AF), with accumulating evidence implicating T-cell subsets, cellular senescence, checkpoint dysfunction, and inflammatory signaling. Although individual studies have provided important insights, a comprehensive synthesis across histological, mechanistic, prognostic, and genetic domains has been lacking. Methods: We systematically reviewed 16 studies published between 2009 and 2025, encompassing histological investigations, translational and mechanistic analyses, interventional cohorts, prognostic studies, and Mendelian randomization. Data on immune cell subsets, cytokines, signaling pathways, and clinical outcomes were extracted. Risk of bias was assessed using ROBINS-I and RoB 2, while certainty of evidence was graded using the GRADE framework. Results: Histological studies consistently demonstrated infiltration of atrial tissue by T lymphocytes and macrophages, with greater intensity in persistent and permanent AF, causally linked to atrial dilatation and fibrosis. Epicardial adipose tissue emerged as a key reservoir of tissue-resident memory T cells that promote IL-17- and IFN-γ-mediated fibroinflammatory remodeling. Mechanistic analyses highlighted CD8+PAR1+ cytotoxic T cells, PD-1/PD-L1 checkpoint disruption, and adipose–myocardial crosstalk as pivotal drivers of AF. Prognostic studies indicated that immune biomarkers provide incremental predictive value beyond conventional risk scores, while genetic evidence supported a causal role for immune dysregulation in AF susceptibility and progression. Conclusions: Across multiple levels of evidence, immune dysregulation is a primary determinant of AF development, progression, and outcomes. Integration of immune biomarkers into clinical practice may enhance risk stratification and inform the design of immune-targeted therapies for atrial fibrillation.

9 October 2024 in Contribuciones A Las Ciencias Sociales
Verified
Journal Article
Open access
PDF file
PPPhabia Assunção Pereira
Phabia Assunção Pereira
ECEduarda Martins Carvalho
Eduarda Martins Carvalho
LBLucas Xavier Boareto
Lucas Xavier Boareto
NMNicolas Felipe Machado
Nicolas Felipe Machado
Henrique Lima de OliveiraHenrique Lima de Oliveira
Henrique Lima de Oliveira
DCDébora Teodoro Carrijo
Débora Teodoro Carrijo
O CRISPR-Cas9 é uma ferramenta da engenharia genética utilizada no melhoramento do DNA, por meio de um corte realizado no genoma seguido do reparo, permitindo a edição de sequências genéticas. Diante disso, pesquisadores estudam a possibilidade de utilizar CRISPR-Cas9 para corrigir mutações genéticas em embriões humanos como a fibrose cística e a anemia falciforme. Dessa forma, este estudo tem como objetivo discutir as questões éticas envolvidas na pesquisa de edição genômica em embriões humanos. Para tanto, foram utilizadas as bases de dados PubMed, com descritores específicos. A busca e triagem criteriosa resultaram na seleção de 7 artigos para revisão. Como resultado, observou-se que as questões éticas são constantemente discutidas. As pesquisas envolvem a utilização de fetos com o destino final sendo o descarte, fato que causa grande comoção. Os principais riscos conhecidos são os efeitos fora do alvo almejado e o mosaicismo. Além disso, o risco existente é inerente à técnica, haja vista que toda técnica de fertilização oferece algum risco. Outra questão relacionada a edição gênica envolve a seleção de características físicas e tecnológicas consideradas boas, sendo, do ponto de vista da psicologia, impossível mensurar os possíveis danos nas próximas gerações. Os principais achados indicam que a ferramenta CRISPR-Cas9 é promissora, com pesquisas relatando o tratamento da distrofia muscular de Duchenne em ratos. Assim, a complexidade ética da temática exige uma abordagem tanto jurídica, quanto um diálogo multidisciplinar e multifacetado envolvendo a população e as áreas saúdes, visando alcançar os benefícios da terapia genômica e esclarecer os questionamentos éticos.

9 June 2026 in Frontiers in Bioscience-Scholar
Verified
Journal Article
Open access
PDF file
Antonio da Silva Menezes JuniorAntonio da Silva Menezes Junior
Antonio da Silva Menezes Junior
Henrique Lima de OliveiraHenrique Lima de Oliveira
Henrique Lima de Oliveira
KLKhissya Beatryz Alves de Lima
Khissya Beatryz Alves de Lima
Background: Hypertrophic cardiomyopathy (HCM) is genetically heterogeneous and characterized by left ventricular hypertrophy, myocardial fibrosis, and diverse clinical manifestations. Although circulating microRNAs (miRNAs) are promising biomarkers of pathological cardiac remodeling, the correlation of these miRNAs with specific clinical characteristics of HCM remains unclear. Therefore, we systematically reviewed and quantified the correlation between circulating miRNAs and structural and functional cardiac parameters in HCM. Methods: This systematic review and meta-analysis of observational studies evaluated the association between circulating miRNA expression levels and Echocardiography, magnetic resonance imaging, and histological parameters for HCM. We comprehensively searched the PubMed, Embase, Scopus, and Web of Science databases, and extracted and transformed correlation coefficients into Fisher’s Z-scores. The study was registered with PROSPERO under registration number CRD420251058653. Meta-analyses were conducted using random-effects models, and heterogeneity was assessed using the I2 statistic. Sensitivity analyses, meta-regression, and publication bias were also assessed. Results: A total of 11 studies comprising 633 patients were included. Pooled analysis showed moderate-to-strong positive correlations between miRNAs (miR-21, miR-29a, miR-199a-5p, and miR-27a) and myocardial fibrosis, wall thickness, and left ventricular mass (r = 0.53; 95% confidence interval 0.40–0.64; I2 = 60.1%). Sensitivity and meta-regression analyses confirmed the robustness of the results, with no significant publication bias. The risk-of-bias assessment (Quality Assessment of Diagnostic Accuracy Studies 2) revealed moderate concerns, primarily related to patient selection and index-test blinding. Conclusion: Circulating miRNAs were significantly correlated with structural and functional cardiac changes in HCM, supporting the potential role of these miRNAs as noninvasive biomarkers. However, further high-quality studies are needed to validate their clinical applicability.